Philip Bedford
Career history of Philip Bedford
Former positions of Philip Bedford
| Companies | Position | Start | End |
|---|---|---|---|
| Glaxo Wellcome Plc | Corporate Officer/Principal | 01/01/1997 | 01/01/1997 |
Acambis Plc
 Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Chief Tech/Sci/R&D Officer | - | - |
| General Counsel | - | - | |
Adjuvantix Ltd.
 Adjuvantix Ltd. BiotechnologyHealth Technology Adjuvantix Ltd. engages in the research and development of vaccines for the treatment of cancer and infectious diseases. Its initial vaccine development targets include prostate cancer, lymphoma and TB. The company's products include ADX40-TB, ADX40-prostate cancer and ADX40-lymphoma. Adjuvantix was founded by Andrew John William Heath on October 28, 1999 and is headquartered in Sheffield, the United Kingdom. | Director/Board Member | 16/10/2009 | - |
Statistics
International
| United Kingdom | 4 |
Operational
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Health Technology | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
| Glaxo Wellcome Plc | Health Technology |
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Health Technology |
Adjuvantix Ltd.
Adjuvantix Ltd. BiotechnologyHealth Technology Adjuvantix Ltd. engages in the research and development of vaccines for the treatment of cancer and infectious diseases. Its initial vaccine development targets include prostate cancer, lymphoma and TB. The company's products include ADX40-TB, ADX40-prostate cancer and ADX40-lymphoma. Adjuvantix was founded by Andrew John William Heath on October 28, 1999 and is headquartered in Sheffield, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Philip Bedford
- Experience
